poisar

Stocks · News reference

Atea Pharmaceuticals Says Topline Data From C-BEYOND Phase 3 Trial Of Once-daily Fixed-Dose Combination Of Bemnifosbuvir and Ruzasvir for Chronic Hepatitis C Virus Infection Shows Statistical Non-Inferiority Vs. Fixed-Dose Combination Of Sofosbuvir and Velpatasvir

Jul 28, 2026, 11:09 AMBenzinga Newsdesk

In the mITT analysis (n=905, cirrhotic and non-cirrhotic), BEM/RZR achieved a 93.9% sustained virologic response (SVR) rate vs. 94.8% for SOF/VEL (Epclusa) at Week 24, encompassing SVR at 12 weeks post-treatment

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

AVIR
Source
benzinga
Observed
Jul 28, 2026, 11:09 AM
Checked
Jul 28, 2026, 11:09 AM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading